192 related articles for article (PubMed ID: 33588158)
41. An integrated biomarker of PD-L1 expression and intraepithelial CD8
Li LL; Zhou DX; Lu M; Zhou D; Lin XF; Chen Y; Yin K; Feng HB; Guo WB; Xie Z; Yan WQ; Lv ZY; Lu DX; Zhang SL; Zhang XC
Thorac Cancer; 2022 Jul; 13(13):1948-1960. PubMed ID: 35596539
[TBL] [Abstract][Full Text] [Related]
42. Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse.
Nardone V; Botta C; Caraglia M; Martino EC; Ambrosio MR; Carfagno T; Tini P; Semeraro L; Misso G; Grimaldi A; Boccellino M; Facchini G; Berretta M; Vischi G; Rocca BJ; Barone A; Tassone P; Tagliaferri P; Del Vecchio MT; Pirtoli L; Correale P
Cancer Biol Ther; 2016 Nov; 17(11):1213-1220. PubMed ID: 27791459
[TBL] [Abstract][Full Text] [Related]
43. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
[TBL] [Abstract][Full Text] [Related]
44. Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma.
Cai C; Xu YF; Wu ZJ; Dong Q; Li MY; Olson JC; Rabinowitz YM; Wang LH; Sun Y
World J Urol; 2016 Apr; 34(4):561-7. PubMed ID: 26253654
[TBL] [Abstract][Full Text] [Related]
45. Analysis of the inflammatory tumor microenvironment in meningeal neoplasms.
Berghoff AS; Kresl P; Rajky O; Widhalm G; Ricken G; Hainfellner JA; Marosi C; Birner P; Preusser M
Clin Neuropathol; 2020; 39(6):256-262. PubMed ID: 32831157
[TBL] [Abstract][Full Text] [Related]
46. Identification of an enriched CD4+ CD8alpha++ CD8beta+ T-cell subset among tumor-infiltrating lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Dal Cin P; Van den Berghe H; Ceuppens JL
Int J Cancer; 1997 Apr; 71(2):178-82. PubMed ID: 9139839
[TBL] [Abstract][Full Text] [Related]
47. Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in
Isomoto K; Haratani K; Hayashi H; Shimizu S; Tomida S; Niwa T; Yokoyama T; Fukuda Y; Chiba Y; Kato R; Tanizaki J; Tanaka K; Takeda M; Ogura T; Ishida T; Ito A; Nakagawa K
Clin Cancer Res; 2020 Apr; 26(8):2037-2046. PubMed ID: 31937613
[TBL] [Abstract][Full Text] [Related]
48. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
[TBL] [Abstract][Full Text] [Related]
49. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin.
Remark R; Alifano M; Cremer I; Lupo A; Dieu-Nosjean MC; Riquet M; Crozet L; Ouakrim H; Goc J; Cazes A; Fléjou JF; Gibault L; Verkarre V; Régnard JF; Pagès ON; Oudard S; Mlecnik B; Sautès-Fridman C; Fridman WH; Damotte D
Clin Cancer Res; 2013 Aug; 19(15):4079-91. PubMed ID: 23785047
[TBL] [Abstract][Full Text] [Related]
50. Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.
Herrera-Rios D; Mughal SS; Teuber-Hanselmann S; Pierscianek D; Sucker A; Jansen P; Schimming T; Klode J; Reifenberger J; Felsberg J; Keyvani K; Brors B; Sure U; Reifenberger G; Schadendorf D; Helfrich I
Front Immunol; 2020; 11():120. PubMed ID: 32117271
[TBL] [Abstract][Full Text] [Related]
51. Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8
Hladíková K; Koucký V; Bouček J; Laco J; Grega M; Hodek M; Zábrodský M; Vošmik M; Rozkošová K; Vošmiková H; Čelakovský P; Chrobok V; Ryška A; Špíšek R; Fialová A
J Immunother Cancer; 2019 Oct; 7(1):261. PubMed ID: 31623665
[TBL] [Abstract][Full Text] [Related]
52. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Krieger T; Pearson I; Bell J; Doherty J; Robbins P
Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
[TBL] [Abstract][Full Text] [Related]
53. Heterogeneity of PD-L1 expression and CD8 lymphocyte infiltration in metastatic colorectal cancer and their prognostic significance.
Xin H; Zhou C; Wang G; Liu Y; Zhang J; Liu Y; Li B; Zhang J; Su M; Li Z; Wang G
Heliyon; 2023 Feb; 9(2):e13048. PubMed ID: 36814622
[TBL] [Abstract][Full Text] [Related]
54. Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer.
Mitchell KG; Negrao MV; Parra ER; Li J; Zhang J; Dejima H; Vaporciyan AA; Swisher SG; Weissferdt A; Antonoff MB; Cascone T; Roarty E; Wistuba II; Heymach JV; Gibbons DL; Zhang J; Sepesi B
Ann Thorac Surg; 2020 Feb; 109(2):358-366. PubMed ID: 31550464
[TBL] [Abstract][Full Text] [Related]
55. Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
Liu XD; Hoang A; Zhou L; Kalra S; Yetil A; Sun M; Ding Z; Zhang X; Bai S; German P; Tamboli P; Rao P; Karam JA; Wood C; Matin S; Zurita A; Bex A; Griffioen AW; Gao J; Sharma P; Tannir N; Sircar K; Jonasch E
Cancer Immunol Res; 2015 Sep; 3(9):1017-29. PubMed ID: 26014097
[TBL] [Abstract][Full Text] [Related]
56. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
Lo CS; Sanii S; Kroeger DR; Milne K; Talhouk A; Chiu DS; Rahimi K; Shaw PA; Clarke BA; Nelson BH
Clin Cancer Res; 2017 Feb; 23(4):925-934. PubMed ID: 27601594
[No Abstract] [Full Text] [Related]
57. Low PD-1 Expression in Cytotoxic CD8
Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
[No Abstract] [Full Text] [Related]
58. The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma.
Gurin D; Slavik M; Hermanova M; Selingerova I; Kazda T; Hendrych M; Shatokhina T; Vesela M
J Oral Pathol Med; 2020 Oct; 49(9):886-896. PubMed ID: 32516834
[TBL] [Abstract][Full Text] [Related]
59. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
60. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
